Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
- Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021
- The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet
- Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it
- Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study
Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap investing, bringing together shareholders, entrepreneurs, and investors.
George Jurcic, the head of Investor Relations (“IR”) at Lexaria, represented the company. He was among 50 other speakers who took the stage in this event that featured 15-minute company presentations, educational sessions from expert analysts and traders, and insights on Small Caps across a broad range of industries (https://nnw.fm/itfUX).
The Benzinga Global Small Cap Conferences have always linked Small Cap companies, traders, and investors. It represents an important opportunity for interested parties to explore the available investment opportunities and learn about small cap investing with clearly-defined educational modules and well-curated small cap investment opportunities.
The event came just after Lexaria announced its most ambitious study yet- HYPER-H21-4. This study will evaluate the company’s patented DehydraTECH(TM)-processed CBD to treat heart disease and hypertension. It builds on the two previous studies, HYPER-H21-1 and HYPER-H21-2, both of which have been successful (https://nnw.fm/X15Dr).
Lexaria continues to innovate with its drug delivery platforms. With over 23 issued patents and more than 50 pending patents in 40 countries worldwide, this company is committed to becoming the undisputed industry leader in enhancing the speed and efficiency of orally-delivered fat-soluble active drugs and molecules. Furthermore, Lexaria focuses on different commercial opportunities to offer solutions to consumers and value to shareholders with its four subsidiary enterprises.
Going forward, Lexaria plans to sub-license its DehydraTECH technology across the world, allowing for more people to benefit from it and improve their quality of life. So far, the technology has proven promising in anti-viral treatments and the treatment of hypertension and heart disease, among others. Through its research and technology program, Lexaria is also pursuing potential solutions to individuals struggling to quit smoking. In a recently concluded study on canines, the company’s DehydraTECH technology showed a 10-20 times faster nicotine delivery into the bloodstream, a factor that should provide much greater customer satisfaction (https://nnw.fm/Wz7P3).
For the 2022 calendar year, Lexaria plans to report results on its HYPER-H21-3 clinical study, and it also looks forward to the “IRB approval for its Hyper-H21-4 study.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021
- The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet
- Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it
- Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study
Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap investing, bringing together shareholders, entrepreneurs, and investors.
George Jurcic, the head of Investor Relations (“IR”) at Lexaria, represented the company. He was among 50 other speakers who took the stage in this event that featured 15-minute company presentations, educational sessions from expert analysts and traders, and insights on Small Caps across a broad range of industries (https://nnw.fm/itfUX).
The Benzinga Global Small Cap Conferences have always linked Small Cap companies, traders, and investors. It represents an important opportunity for interested parties to explore the available investment opportunities and learn about small cap investing with clearly-defined educational modules and well-curated small cap investment opportunities.
The event came just after Lexaria announced its most ambitious study yet- HYPER-H21-4. This study will evaluate the company’s patented DehydraTECH(TM)-processed CBD to treat heart disease and hypertension. It builds on the two previous studies, HYPER-H21-1 and HYPER-H21-2, both of which have been successful (https://nnw.fm/X15Dr).
Lexaria continues to innovate with its drug delivery platforms. With over 23 issued patents and more than 50 pending patents in 40 countries worldwide, this company is committed to becoming the undisputed industry leader in enhancing the speed and efficiency of orally-delivered fat-soluble active drugs and molecules. Furthermore, Lexaria focuses on different commercial opportunities to offer solutions to consumers and value to shareholders with its four subsidiary enterprises.
Going forward, Lexaria plans to sub-license its DehydraTECH technology across the world, allowing for more people to benefit from it and improve their quality of life. So far, the technology has proven promising in anti-viral treatments and the treatment of hypertension and heart disease, among others. Through its research and technology program, Lexaria is also pursuing potential solutions to individuals struggling to quit smoking. In a recently concluded study on canines, the company’s DehydraTECH technology showed a 10-20 times faster nicotine delivery into the bloodstream, a factor that should provide much greater customer satisfaction (https://nnw.fm/Wz7P3).
For the 2022 calendar year, Lexaria plans to report results on its HYPER-H21-3 clinical study, and it also looks forward to the “IRB approval for its Hyper-H21-4 study.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
